Providing complex support in analytics and bioanalytics of large molecules, a BioPharma department’s capabilities help get more efficient drugs to patients and subsequently improve quality of life.

An essential part of QUINTA-ANALYTICA’s service portfolio, its BioPharma team offers comprehensive support via the testing of large, more complex pharmaceutical products such as peptides, proteins, monoclonal antibodies, and antibody-drug conjugates.

Led by Milan Madera, who has a strong background in characterization using chromatographic and mass spectrometric techniques, the dept. is equipped with modern high resolution/high mass accuracy LC-MS/MS, capillary electrophoresis designed for biopharma applications, and ELISA readers with a state-of-the-art MSD electrochemiluminescence platform which allows for immunogenicity testing of therapeutic drugs.

Despite being the newest dept. of Quinta, its operation in R&D, GMP, GLP, and GCP regimes help clients through the development and validations of methods not only for routine analysis of therapeutic products but also as bioanalytical support for preclinical and clinical testing.

If you’re looking for characterization of complex analytes or their quantification in various biological matrices, get in touch with Milan or the rest of the team today.

Additional News

  • 3 September 2026

    Quinta-Analytica Expands HPLC Fleet to Strengthen Flexibility and Capacity for Clients

    New Thermo Scientific Vanquish Core joins an HPLC fleet of around 50 systems

  • 7 August 2026

    Quinta-Analytica at CPHI Milan 2026 – Meet Us at Conscio Group Stand 6N25

    Meet Quinta-Analytica at CPHI Milan 2026 as part of the Conscio Group team at Stand 6N25. Discuss your clinical, bioanalytical and analytical projects with our experts and arrange a meeting in advance.

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.